| DC4157 |
Dovitinib (TKI258, CHIR258)
Featured
|
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
|
| DC10313 |
Dovitinib lactate |
Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. |
|
| DC11726 |
Milademetan
Featured
|
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis. |
|
| DC9755 |
eFT508(Tomivosertib)
Featured
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
|
| DC5057 |
Enzastaurin (LY317615)
Featured
|
Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3. |
|
| DC7927 |
EPZ011989
Featured
|
EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
|
| DC11387 |
Erdafitinib
Featured
|
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively. |
|
| DC8342 |
EW-7197
Featured
|
EW-7197 is a potent ALK5 inhibitor. EW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy. |
|
| DC2014 |
Flavopiridol
Featured
|
Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM, and CDK7 with IC50 of 300 nM. |
|
| DC8780 |
Flavopiridol Hydrochloride
Featured
|
Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. |
|
| DC8164 |
Gilteritinib(ASP2215)
Featured
|
FLT3/AXL inhibitor |
|
| DC8174 |
Pexmetinib(ARRY-614)
Featured
|
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia. |
|
| DC10485 |
GDC0575（ARRY-575，RG7441）
Featured
|
GDC0575（ARRY-575，RG7441）is a small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. |
|
| DC5147 |
Molibresib (I-BET-762)
Featured
|
GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4). |
|
| DC10647 |
EPZ015938(pemrametostat)
Featured
|
GSK3326595(EPZ015938) is the first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor. |
|
| DC2070 |
GSK690693
Featured
|
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
|
| DC11262 |
IACS-010759
Featured
|
IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain. |
|
| DC10174 |
Iberdomide
Featured
|
Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay. |
|
| DC3130 |
ICG-001
Featured
|
ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro |
|
| DC4181 |
Imatinib mesylate
Featured
|
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
|
| DC5072 |
Duvelisib (IPI-145, INK1197)
Featured
|
IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. |
|
| DC12378 |
Itacitinib(INCB039110)
Featured
|
Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. |
|
| DC7067 |
KPT-330(Selinexor)
Featured
|
KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor. |
|
| DC8522 |
KW-2449
Featured
|
KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. |
|
| DC7449 |
KW-2478
Featured
|
KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1/2 |
|
| DC9837 |
Larotrectinib (LOXO-101 sulfate)
Featured
|
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
|
| DC8541 |
ORY-1001(Ladademstat)
Featured
|
ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
| DC6306 |
LY2157299(Galunisertib)
Featured
|
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
|
| DC7665 |
Gandotinib(LY2784544)
Featured
|
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
|
| DC7019 |
LY-2874455
Featured
|
LY2874455 is a novel and potent FGF/FGFR inhibitor. |
|
